ASCO® 2022

Presentations

SGN-B7H4V | Solid Tumors | Abstract #TPS3155

Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress)